SalaryGuide
SalariesCompaniesJobs
AboutPricingBlog
For Employers

Marketing Jobs in New Jersey

719 marketing jobs

AbbVie logo
3 weeks ago

Marketing Manager I/II, HCP - Psychiatry

AbbVie

Florham Park, NJ (On-site)Full time$110K/yr – $209K/yr
Verizon logo
3 weeks ago

Senior Manager, Paid Search

Verizon

New Jersey, USA (Hybrid)Full time$116K/yr – $201K/yr
BEUMER Group logo
6 weeks ago

Field Marketing Specialist

BEUMER Group

New Jersey, USA (On-site)Full time$85K/yr – $95K/yr
7 weeks ago

Corporate Communications Representative I

Formosa Plastics

Livingston, NJ (On-site)Full time$62K/yr – $86K/yr
7 weeks ago

Digital Advertising Analyst

Fullpath

Teaneck, NJ (Remote)Full time$60K/yr – $85K/yr
Previous
1...242526...
Next

Jobs in New Jersey by role

  • General Marketing
  • Brand Marketing
  • Social Media
  • Communications
  • Content Marketing
  • Marketing Strategy
  • Digital Marketing
  1. Jobs

Marketing jobs in New Jersey

  1. Jobs

Marketing jobs in New Jersey

719 jobs
AbbVie logo

Marketing Manager I/II, HCP - Psychiatry

AbbVie

Florham Park, NJ (On-site)

$110K/yr - $209K/yrIn-houseFull-timeMid level4+ years exp.
3 weeks ago
Verizon logo

Senior Manager, Paid Search

Verizon

New Jersey, USA (Hybrid)

$116K/yr - $201K/yrIn-houseFull-timeSenior level6+ years exp.
3 weeks ago
BEUMER Group logo

Field Marketing Specialist

BEUMER Group

New Jersey, USA (On-site)

$85K/yr - $95K/yrIn-houseFull-timeMid level3+ years exp.
6 weeks ago

Corporate Communications Representative I

Formosa Plastics

Livingston, NJ (On-site)

$62K/yr - $86K/yrIn-houseFull-timeEntry level1+ years exp.
7 weeks ago

Digital Advertising Analyst

Fullpath

Teaneck, NJ (Remote)

$60K/yr - $85K/yrIn-houseFull-timeMid level3+ years exp.
7 weeks ago
Previous1…242526…Next
AbbVie logo
AbbVie

Marketing Manager I/II, HCP - Psychiatry

Florham Park, NJ (On-site)

$110K/yr – $209K/yrMid Level4+ years expFull time

Posted 3 weeks ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • Company news
  • Links

Job Summary

Own and drive end-to-end marketing initiatives from planning through execution, coordinating cross-functional teams and field enablement to deliver measurable business outcomes.

  • Lead programs with market insights, strategy development, and cross-functional alignment
  • Manage timelines, budgets, and agency/vendor partnerships to ensure timely delivery

Job Description

Responsibilities

  • Independently lead assigned marketing initiatives from planning through execution, ensuring timely delivery and strong business outcomes.
  • Maintain a strong understanding of market dynamics, customer needs, and industry trends, leveraging insights to optimize marketing strategy and execution.
  • Lead cross-functional teams and agency partners to execute promotional programs while managing timelines, budgets, and stakeholder expectations.
  • Drive field engagement and enablement through clear communication of key initiatives that support sales force execution.
  • Apply sound judgment and problem-solving skills to navigate challenges, proactively identify risks, and implement solutions that keep projects moving forward

Requirements

  • Bachelor's Degree
  • Marketing experience with proof of building proficiencies in all marketing skills
  • 4-6 years of pharmaceutical and/or CPG marketing
  • Demonstrated understanding of pharmaceutical regulatory requirements and impact on development of marketing materials
  • Experience with digital marketing, including performance monitoring, optimization, and measurement.
  • Proven project management skills with the ability to manage multiple projects and vendors simultaneously with high attention to detail and ability to prioritize among competing business needs
  • Highly organized, proactive professional with strong ownership, adaptability, and intellectual curiosity.
  • Strong written and verbal communication skills, including the ability to present effectively to internal and external stakeholders
  • Ability to influence within a matrixed organization, build cross-functional partnerships, and drive alignment to achieve business objectives.
  • Sound financial acumen and experience managing budgets. Ability to define, track, and analyze key performance indicators and translate findings into actionable business recommendations..

Benefits

  • We offer a comprehensive package of benefits including paid time off (vacation, holidays, sick), medical/dental/vision insurance and 401(k) to eligible employees.
AbbVie logo

AbbVie

4.0 Glassdoor

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Founded in 2013
North Chicago, Illinois, USA
60K employees (3,267 in marketing)
www.abbvie.com
78% recommend to a friend
88% CEO approval

Salaries

Posted range

$110K/yr – $209K/yr

Taken straight from the job posting.

See all AbbVie salaries

Marketing Team

Marketing Team Size
2,942 (5% of company)
Median Career Experience
18 years
Median Tenure
7.6 years
Marketing Roles Posted (Last 30 Days)
31

People

HR / Recruitment

Shavonne Thomas
Shavonne Thomas
Associate Director, Employer Brand & Recruitment Marketing
At the company for 4 years 1 month
Erin Lattin, SHRM-SCP
Erin Lattin, SHRM-SCP
Director, Business HR - International Marketing and Commercial Operations
At the company for 5 years 2 months

Marketing Leadership

Anju Starace
Anju Starace
Associate Vice President, US Marketing, CNS
At the company for 12 years 9 months
Vijay Raghavan
Vijay Raghavan
Associate Vice President Marketing Analytics & Business Insights
At the company for 9 years 9 months
Chrissy Wild
Chrissy Wild
Head of Marketing - Lupron
At the company for 8 years 1 month
Anna Begley
Anna Begley
Head of Marketing, UBRELVY
At the company for 6 years 4 months

Funding

Total Funding
$23B
Last Raise
$8B
Post IPO Debt, 18 days ago

Funding History

  • Feb 2026
    Post IPO Debt • $8B
  • Feb 2024
    Post IPO Debt • $15B
  • Mar 2023
    Post IPO Equity • $250K

Traffic Signals

Monthly Visitors
1.4M
Monthly Google Ads Budget
$37.3K
Traffic Source Mix
Search
35%
Direct
45.7%
Referral
11.2%
Social
6.1%
Paid
1.8%

Headcount Trend

Current headcount: ~59.9K

News about AbbVie

UPDATED: AbbVie to end Calico collab after 11-year run, plans layoffs: Stat
Nov 13, 2025 • Fierce Biotech
AbbVie Ends 11-Year Relationship With Calico, Lays Off 100+
Nov 13, 2025 • BioSpace
AbbVie cuts ties with Google-backed longevity company, lays off scientists
Nov 12, 2025 • statnews.com
Jim Cramer Says “I Found the AbbVie Call Particularly Jarring”
Nov 5, 2025 • Yahoo Finance
Analyst on AbbVie (ABBV): ‘Stay Long’
Nov 3, 2025 • Yahoo Finance
Why AbbVie Stock Flopped on Friday
Nov 1, 2025 • The Motley Fool
AbbVie Beats Third-Quarter Estimates. There’s More to the Drugmaker’s Earnings.
Oct 31, 2025 • Barron's
AbbVie boosts revenue forecast by $400M thanks to booming sales of Skyrizi, Rinvoq
Oct 31, 2025 • Fierce Pharma
AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira ...
Oct 31, 2025 • Yahoo Finance
How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts
Oct 25, 2025 • Yahoo Finance
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
Oct 24, 2025 • Yahoo Finance
AbbVie's Rinvoq shows superiority over Humira in head-to-head arthritis study
Oct 20, 2025 • Reuters
AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors
Oct 13, 2025 • PR Newswire
How pharma giant AbbVie holds leaders accountable for culture
Oct 9, 2025 • Fortune
Why AbbVie Stock Soared in September
Oct 8, 2025 • The Motley Fool
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
Oct 6, 2025 • Yahoo Finance
AbbVie breaks ground on $70m US biologics site amid Trump pressure
Oct 1, 2025 • Pharmaceutical Technology
Why AbbVie Stock Cruised to an Almost 6% Gain Today
Oct 1, 2025 • The Motley Fool
AbbVie charts next leg of US investment journey with $70M expansion in MA
Oct 1, 2025 • Fierce Pharma
AbbVie to launch ovarian cancer drug in UK at US price
Sep 29, 2025 • Reuters
REGENXBIO Announces Presentation at the World Muscle Society
Sep 29, 2025 • PR Newswire
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
Sep 29, 2025 • PR Newswire
United States Cancer Therapeutics Market to Hit $491.6 Billion by 2032, Driven by Precision and Immunotherapy Advances
Sep 29, 2025 • EIN Presswire
September’s FDA Action Bolsters Keytruda, Ultra-Rare Disease but Deals Two SMA Defeats
Sep 29, 2025 • BioSpace
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson’s Disease
Sep 29, 2025 • BioSpace
AbbVie to launch ovarian cancer drug in UK at the same list price as US
Sep 29, 2025 • MarketScreener
Mosaic Consulting Expands Salesforce and Braze Services, Showcases Software Expertise with DrugAlert.ai
Sep 29, 2025 • PR Newswire
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
Sep 29, 2025 • PR Newswire
AbbVie to launch ovarian cancer drug in UK at US price
Sep 29, 2025 • Investing.com
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
Sep 29, 2025 • MarketScreener
District court denies preliminary injunctions by drug companies in challenges to Maine’s 340B contract pharmacy law
Sep 24, 2025 • American Hospital Association
FDA’s Autism Endeavor, Pfizer’s Obesity Comeback Bid, Psychedelics Revival, ACIP Confusion, More
Sep 24, 2025 • BioSpace
Glenmark inks $18 million deal for cancer drug with China’s Hengrui
Sep 24, 2025 • Livemint.com
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies
Sep 24, 2025 • Benzinga.com
Care and Commitment: Celebrating AbbVie's 2025 Working Parents/Caregivers
Sep 23, 2025 • AbbVie
Vernon Hills office hits market as landlord scrambles to cover loan
Sep 23, 2025 • The Real Deal
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Sep 23, 2025 • MarketScreener
Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality
Sep 23, 2025 • PR Newswire
Allergan Aesthetics, an AbbVie company Announces Expansion of SKINVIVE by JUVEDERM into 35 New Markets
Sep 23, 2025 • MarketScreener
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
Sep 23, 2025 • Amneal Pharmaceuticals LLC
AbbVie to Launch Skinvive in 35 Additional Markets
Sep 23, 2025 • MarketScreener
Allergan Aesthetics to Launch Skinvive in 35 New Markets
Sep 23, 2025 • Orange County Business Journal
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 22, 2025 • BioSpace
Parkinson's Disease Therapeutics Market Size to Hit US$ 12.83 Billion by 2033, Report by DataM Intelligence
Sep 22, 2025 • PR Newswire
1 Top Dividend Stock to Buy and Hold Forever
Sep 22, 2025 • The Motley Fool
What Is One of the Best Pharmaceutical Stocks to Buy Right Now?
Sep 22, 2025 • The Motley Fool
Psychedelics Space Enters New Era as AbbVie Dives In
Sep 22, 2025 • BioSpace
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 19, 2025 • Morningstar.com
TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Sep 19, 2025 • MarketScreener
BMO Lifts AbbVie Inc. (ABBV) Price Target to $240 After Rinvoq Litigation Win
Sep 18, 2025 • Yahoo Finance
Roche Makes Major MASH Move With $3.5B 89bio Buy
Sep 18, 2025 • BioSpace
AbbVie just upgraded at Berenberg, here's why
Sep 17, 2025 • thefly.com
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Sep 17, 2025 • Benzinga.com
Berenberg sees opportunity for pharma cos despite policy risks; upgrades Novo
Sep 17, 2025 • Reuters
AbbVie price target raised by $35 at JPMorgan, here's why
Sep 16, 2025 • thefly.com
AbbVie Settles Rinvoq Litigation, Blocks Generics Until 2037
Sep 16, 2025 • Law360
Novo amylin drug underperforms Wegovy in efficacy, but scores in tolerability
Sep 16, 2025 • FierceBiotech
Genmab discards clinical ADC picked up in last year's $1.8B ProfoundBio buy
Sep 16, 2025 • FierceBiotech
Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
Sep 16, 2025 • Morningstar.com
FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters
Sep 16, 2025 • FiercePharma
Maricel Torrent Recognized by Influential Women 2025
Sep 15, 2025 • EIN Presswire
Saisei Ventures Appoints James Feliciano as Venture Partner
Sep 15, 2025 • Venture Capital Firms
AbbVie broadens its telisotuzumab conjugate push | ApexOnco - Clinical Trials news and analysis
Sep 12, 2025 • Oncology Pipeline
AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement
Sep 12, 2025 • BioSpace
Dow Jones Top Company Headlines at 9 PM ET: Microsoft, OpenAI Truce Clears Hurdle in Path to For-Profit Conversion | Adobe ...
Sep 12, 2025 • Morningstar.com
Wells sees AbbVie Rinvoq settlement being worth $11-$24 per share
Sep 11, 2025 • thefly.com
AbbVie price target raised by $25 at BMO Capital, here's why
Sep 11, 2025 • thefly.com
AbbVie in Settlement With Generic Drugmakers on Rinvoq
Sep 11, 2025 • Morningstar.com
AbbVie shares hit record high as key immunology drug set for exclusivity until 2037
Sep 11, 2025 • MarketScreener
AbbVie stock rises after securing patent protection for RINVOQ until 2037
Sep 11, 2025 • Yahoo Finance - Business Finance, Stock Market, Quotes, News
Dow Jones Top Company Headlines at 3 PM ET: Paramount Skydance Prepares Ellison-Backed Bid for Warner Bros. Discovery | AbbVie ...
Sep 11, 2025 • Morningstar.com
AbbVie On Pace For Record High Close — Data Talk
Sep 11, 2025 • Morningstar.com
AbbVie jumps 4% to $220.77 after settling with Rinvoq generic makers
Sep 11, 2025 • thefly.com
Dow Jones Top Company Headlines at 3 PM ET: Paramount Skydance Prepares Ellison-Backed Bid for Warner Bros. Discovery | AbbVie ...
Sep 11, 2025 • Dow Jones Newswires
Glenmark gains 3% on $700 mn upfront payment from AbbVie licensing deal
Sep 9, 2025 • Business Standard India
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils "The One & Only" Campaign Featuring Real People and Their Distinctive Stories
Sep 9, 2025 • PR Newswire
Glenmark Pharma shares rise as arm receives an upfront payment of $700 mn
Sep 9, 2025 • Business Standard India
Transcript : AbbVie Inc. Presents at Morgan Stanley 23rd Annual Global Healthcare Conference, Sep-09-2025 10
Sep 9, 2025 • MarketScreener
Glenmark Pharma subsidiary IGI gets $700 million upfront payment from AbbVie
Sep 9, 2025 • Hindu Business Line
1 Reason Every Investor Should Know About AbbVie (ABBV)
Sep 8, 2025 • The Motley Fool
"Anti-Parkinson's Drugs: Global Markets to 2030"
Sep 8, 2025 • PharmiWeb
Trump’s factory boom stalled for now as payrolls keep shrinking
Sep 6, 2025 • Boston Herald
Run. Rally. Rise. The 2025 Race to End Women's Cancer is Back in Washington, D.C.
Sep 5, 2025 • PR Newswire
AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial
Sep 4, 2025 • Clinical Trials Arena
Don't miss out on these 2 stocks, say analysts at MOFSL; details inside
Sep 4, 2025 • Business Standard India
After 2021 SPAC Bubble, How Did These 6 Biotechs Fare?
Sep 3, 2025 • BioSpace
Antitrust Softens, Yields Still Rise
Sep 3, 2025 • MarketScreener
AbbVie reports results from Phase 2 EPCORE NHL-6 trial
Sep 3, 2025 • thefly.com
Genmab Announces Updated Results from Phase 2 EPCORE® NHL...
Sep 3, 2025 • PharmiWeb
Global drugmakers rush to boost US presence as tariff threat looms
Sep 3, 2025 • MarketScreener
Allergan Aesthetics Launches Campaign to Educate Consumers about Hyaluronic Acid (HA) Injectable Fillers
Sep 3, 2025 • PR Newswire
Multiple Myeloma Market Size Projected USD 49.89 Billion by 2034
Sep 3, 2025 • Precedence Research
AbbVie Gets Health Canada Approval for Ovarian-Cancer Treatment
Sep 2, 2025 • MarketScreener
Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers Français
Sep 2, 2025 • Canada NewsWire
AbbVie Says Health Canada Approves Elahere in Some Types of Ovarian Cancers
Sep 2, 2025 • MarketScreener
AbbVie Named to 2025 Best Workplaces in Asia List by Great Place To Work
Sep 1, 2025 • prnasia.com
JLS Fund Congratulates Largest Portfolio Holding, Gilamesh Pharmaceuticals on $1.2 Billion Deal with AbbVie (NYSE: ABBV)
Sep 1, 2025 • EIN Presswire
Blood Cancer Awareness Month: What biotech holds in store
Sep 1, 2025 • Labiotech.eu
5 High-Yield Dividend Stocks I Plan on Holding for the Next 10 Years or Longer
Aug 31, 2025 • The Motley Fool
Great Place to Work Middle East announces the 2025 Best Workplaces in Asia
Aug 30, 2025 • Zawya.com

Links

www.abbvie.comLinkedInX (Twitter)Crunchbase

This role is listed on SalaryGuide for informational purposes. SalaryGuide is not the employer, recruitment agency, or hiring representative for this position. Hiring decisions and the application process are managed by the employer. SalaryGuide will never ask candidates to pay to apply for a job or request bank details or identification documents as part of an application.